Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy

Journal of Hematology & Oncology

Evan Y. Yu²  Colleen Soleau¹  Heather H. Cheng³ 

[1] University of Washington, Seattle, USA;Division of Medical Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, Seattle 98109, WA, USA;Fred Hutchinson Cancer Research Center, Seattle, USA

关键词: Prostate-specific antigen (PSA);    Immunotherapy;    Sipuleucel-T;    Chronic lymphocytic leukemia (CLL);    Prostate cancer;   

Others  :  1217414
DOI  :  10.1186/s13045-015-0149-x

 received in 2015-04-22, accepted in 2015-05-06,  发布年份 2015

【 摘 要 】

Prostate cancer and chronic lymphocytic leukemia (CLL) are relatively common malignancies associated with advanced age. Although immunotherapy-based strategies are used to treat both, currently, there is no overlap in specific therapies. Sipuleucel-T is an active cellular immunotherapy that improves overall survival for patients with metastatic castration resistant prostate cancer (mCRPC) but is not typically associated with a decline in prostate-specific antigen (PSA) following administration. We report the case of a 78-year-old man with mCRPC and Rai stage 0 CLL who sustained a 12-month decline in both PSA and white blood cell (WBC) count following treatment with APC8015-2 (an investigational form of sipuleucel-T), as part of the phase II ProACT clinical trial. Two years later, the patient received commercial sipuleucel-T and again was noted to have a decline in PSA. Exploratory analysis did not clearly identify any peripheral immune markers associated with response. This case report suggests that treatment with sipuleucel-T can rarely lead to PSA decline, may have dual activity against both prostate cancer and CLL, and that these findings warrant further investigation.

【 授权许可】

   
2015 Cheng et al.; licensee BioMed Central.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al.. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363:411-22.
• [2]Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN et al.. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014; 32:3436-48.
• [3]Jobsis AC, De Vries GP, Meijer AE, Ploem JS. The immunohistochemical detection of prostatic acid phosphatase: its possibilities and limitations in tumour histochemistry. Histochem J. 1981; 13:961-73.
• [4]Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2004:163–83
• [5]Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014; 312:2265-76.
• [6]Wu M, Akinleye A, Zhu X. Novel agents for chronic lymphocytic leukemia. J Hematol Oncol. 2013; 6:36. BioMed Central Full Text
• [7]Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A et al.. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011; 3:95ra73.
• [8]Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365:725-33.
• [9]Han EQ, Li XL, Wang CR, Li TF, Han SY. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol. 2013; 6:47. BioMed Central Full Text
• [10]Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY et al.. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother. 2013; 62:137-47.
• [11]Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV et al.. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000; 18:3894-903.
• [12]Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW et al.. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate. 2004; 60:197-204.
• [13]So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther. 2006; 6:1163-7.
• [14]GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher T, Hall SJ, et al. Humoral immune response against non-targeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome. Clin Cancer Res. 2015. [Epub ahead of print]
• [15]Kharfan-Dabaja MA, Wierda WG, Cooper LJ. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia. 2014; 28:507-17.
• [16]Palma M, Hansson L, Choudhury A, Näsman-Glaser B, Eriksson I, Adamson L et al.. Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria. Cancer Immunol Immunother. 2012; 61:865-79.
• [17]Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M et al.. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013; 123:3756-65.
• [18]Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, Kumar S, Buadi F et al.. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol. 2009; 84:799-802.